• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $DRNA

    Dicerna Pharmaceuticals, Inc.

    Subscribe to $DRNA
    $DRNA
    Major Pharmaceuticals
    Health Care

    Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: dicerna.com

    Peers

    $ALNA
    $ALNY

    Recent Analyst Ratings for Dicerna Pharmaceuticals, Inc.

    DatePrice TargetRatingAnalyst
    12/9/2021$28.00 → $38.25Buy → Neutral
    Chardan Capital
    11/19/2021$30.00 → $38.25Outperform → Sector Perform
    RBC Capital
    11/18/2021$32.00 → $38.25Buy → Neutral
    HC Wainwright & Co.
    8/11/2021$36.00 → $25.00Buy → Neutral
    Goldman Sachs
    8/10/2021$34.00 → $28.00Buy
    Chardan Capital
    8/10/2021$38.00 → $32.00Buy
    HC Wainwright & Co.
    8/9/2021$32.00Buy → Neutral
    Citigroup
    8/6/2021$35.00 → $30.00Outperform
    RBC Capital
    8/6/2021$48.00 → $36.00Buy
    Goldman Sachs
    8/6/2021$54.00 → $47.00Outperform
    SVB Leerink
    See more ratings

    Dicerna Pharmaceuticals, Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dicerna Pharmaceuticals downgraded by Chardan Capital with a new price target

      Chardan Capital downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $38.25 from $28.00 previously

      12/9/21 4:59:39 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Pharmaceuticals downgraded by RBC Capital with a new price target

      RBC Capital downgraded Dicerna Pharmaceuticals from Outperform to Sector Perform and set a new price target of $38.25 from $30.00 previously

      11/19/21 5:44:25 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Pharmaceuticals downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $38.25 from $32.00 previously

      11/18/21 11:53:19 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Pharmaceuticals downgraded by Goldman Sachs with a new price target

      Goldman Sachs downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $25.00 from $36.00 previously

      8/11/21 4:53:56 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Chardan Capital reiterated coverage on Dicerna Pharmaceuticals with a new price target

      Chardan Capital reiterated coverage of Dicerna Pharmaceuticals with a rating of Buy and set a new price target of $28.00 from $34.00 previously

      8/10/21 8:55:38 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • HC Wainwright & Co. reiterated coverage on Dicerna Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Dicerna Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $38.00 previously

      8/10/21 6:36:41 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Pharmaceuticals downgraded by Citigroup with a new price target

      Citigroup downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $32.00

      8/9/21 6:13:44 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • RBC Capital reiterated coverage on Dicerna Pharmaceuticals with a new price target

      RBC Capital reiterated coverage of Dicerna Pharmaceuticals with a rating of Outperform and set a new price target of $30.00 from $35.00 previously

      8/6/21 10:23:30 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Goldman Sachs reiterated coverage on Dicerna Pharmaceuticals with a new price target

      Goldman Sachs reiterated coverage of Dicerna Pharmaceuticals with a rating of Buy and set a new price target of $36.00 from $48.00 previously

      8/6/21 8:20:44 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SVB Leerink reiterated coverage on Dicerna Pharmaceuticals with a new price target

      SVB Leerink reiterated coverage of Dicerna Pharmaceuticals with a rating of Outperform and set a new price target of $47.00 from $54.00 previously

      8/6/21 8:07:30 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    Dicerna Pharmaceuticals, Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

      Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. ((Dicerna, NASDAQ:DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021,

      12/28/21 9:04:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

      Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Novo Nordisk's cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021. As previously announced on November 18, 2021, Novo Nordisk commenced a cash tender offer to purchase all outstanding shares of Dicerna common stock for $38.25 per share in cash, without interest and subject to any withholding of taxes. The expiration of the HSR waiting period satisfies one of the conditions necessary for the consummation of the tender offer. Other conditions remain to be satisfied, inclu

      12/25/21 8:00:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Direxion Launches mRNA ETF (MSGR)

      NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR). MSGR invests in companies believed to be at the forefront of the development and application of messenger RNA technology. The MSGR ETF seeks investment results, before fees and expenses, of the BITA Messenger RNA Technology Index. The BITA Messenger RNA Technology Index provides exposure to the performance of companies, publicly listed in the United States, Canada and Europe, that are leading the development and application of mRNA technology. mRNA is a single-stranded ribonucleic acid molecule that is complementary to one of the DNA strands of a gene. mRNA plays a vital role i

      12/9/21 8:41:00 AM ET
      $ALNY
      $ARWR
      $BGNE
      $BNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Major Pharmaceuticals
    • Novo Nordisk to Acquire Dicerna

      – Acquisition to Accelerate and Expand Novo Nordisk Development of RNAi Therapeutics Using Dicerna's Proprietary GalXC™ Technology Platform – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, for $38.25 per share in cash, which represents a total equity value of $3.3 billion and a premium of 80% to Dicerna's closing price on November 17, 2021. The transaction was unanimously approved by the Dicerna Board of Directors and the Board of Directors of

      11/18/21 7:00:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly

      – Milestone Triggers Two Single-Digit Multimillion-Dollar Payments to Dicerna – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Eli Lilly and Company ("Lilly") has declared proof of principle for the first two targets in the companies' exclusive relationship in neurodegeneration and pain, under the companies' global research and licensing collaboration. This milestone triggers two single-digit multimillion-dollar milestone payments to Dicerna, which the Company expects to receive in the fourth quarter of 2021. "We are very pleased to announce Lilly's selection of two extrahepatic ta

      11/12/21 8:10:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

      – Belcesiran Was Shown to Be Safe and Well Tolerated in Phase 1 Trial and Demonstrated Robust, Dose-Dependent Reductions in Serum Alpha-1 Antitrypsin –  – Enrollment in ESTRELLA Phase 2 Study of Belcesiran Is Ongoing; Global Rollout to Additional Trial Sites Continues – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today presented results from its Phase 1 double-blind, placebo-controlled, randomized trial of belcesiran, an investigational GalXC™ RNAi therapeutic in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease (AATLD). These data expand upon interim res

      11/12/21 8:00:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

      – Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) – – Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol Use Disorder (AUD) – – Company Plans to Unveil First GalXC-Plus™ Extrahepatic Target in Early 2022 – – Cash Runway Extends Into 2025 – – Company to Host Conference Call Today at 8:30 a.m. ET – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended September 30, 2021 and provided a business update. "We had a

      11/9/21 7:30:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021

       – Nedosiran Achieved Primary Endpoint Demonstrating Statistically Significant Sustained Reduction in Urinary Oxalate Excretion and Showed Robust Efficacy in PH1 – – Real-World Healthcare Utilization Data Showed Delayed Diagnosis in More Than 50% of Patients, High Rates of Healthcare Use and Substantial Costs Following Start of Dialysis – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced results of the PHYOX™2 pivotal clinical trial of nedosiran, an investigational GalXC™ RNAi candidate for the treatment of primary hyperoxaluria (PH), in a late-breaker poster presentation at the American S

      11/4/21 1:15:00 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021

      Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2021 financial results before market open on Tuesday, Nov. 9, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website. The conference call can be accessed by dialing (855) 4

      11/2/21 4:05:00 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    Dicerna Pharmaceuticals, Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Koppel Adam closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:43:55 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Zeng Ling closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:22:27 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Weissman James B closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:22:10 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Smith Cynthia closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:21:51 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Pagan Douglas W. closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:21:31 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Kozin Marc D returned $433,487 worth of shares to the company (11,333 units at $38.25), closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:21:05 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Hoffman Stephen J closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:20:44 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Gray Patrick M. closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:20:28 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Freed Martin I closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:20:11 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Fambrough Douglas returned $8,852,236 worth of shares to the company (231,431 units at $38.25), closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:19:54 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    Dicerna Pharmaceuticals, Inc. SEC Filings

    See more
    • SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.

      15-12B - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      1/10/22 4:59:18 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.

      EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      1/3/22 12:15:12 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.

      EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      1/3/22 12:15:18 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.

      EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      1/3/22 12:15:22 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.

      EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      1/3/22 12:15:26 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form POSASR filed by Dicerna Pharmaceuticals, Inc.

      POSASR - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      12/28/21 11:17:58 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form POS AM filed by Dicerna Pharmaceuticals, Inc.

      POS AM - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      12/28/21 11:14:51 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form POS AM filed by Dicerna Pharmaceuticals, Inc.

      POS AM - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      12/28/21 11:13:28 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form POS AM filed by Dicerna Pharmaceuticals, Inc.

      POS AM - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      12/28/21 11:11:58 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form POS AM filed by Dicerna Pharmaceuticals, Inc.

      POS AM - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      12/28/21 11:10:53 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    Dicerna Pharmaceuticals, Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Dicerna Announces New Executive Leadership Appointments

      – Rob Ciappenelli Appointed Chief Strategy Officer and Marc Abrams, Ph.D., Promoted to Senior Vice President of Discovery Research – – Kristen Sheppard, Esq., Joins Company as Senior Vice President of Investor Relations and Corporate Communications – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Rob Ciappenelli as Chief Strategy Officer, the promotion of Marc Abrams, Ph.D., to Senior Vice President, Discovery Research and the addition of Kristen Sheppard, Esq., to Dicerna's executive leadership team as Senior Vice President, Investor Rela

      9/22/21 7:30:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 23,350 shares of common stock and 5,675 restricted stock units (“RSUs”) to be distributed among three new employees with a grant date of Jan. 4, 2021 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $22.07

      1/4/21 5:30:00 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,

      12/1/20 4:30:00 PM ET
      $LLY
      $DRNA
      $NVO
      $ALXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    Dicerna Pharmaceuticals, Inc. Financials

    Live finance-specific insights

    See more
    • Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

      Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. ((Dicerna, NASDAQ:DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021,

      12/28/21 9:04:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

      – Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) – – Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol Use Disorder (AUD) – – Company Plans to Unveil First GalXC-Plus™ Extrahepatic Target in Early 2022 – – Cash Runway Extends Into 2025 – – Company to Host Conference Call Today at 8:30 a.m. ET – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended September 30, 2021 and provided a business update. "We had a

      11/9/21 7:30:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021

      Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2021 financial results before market open on Tuesday, Nov. 9, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website. The conference call can be accessed by dialing (855) 4

      11/2/21 4:05:00 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update

      – Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria – – Announced U.S. Food and Drug Administration (FDA) Clearance of Investigational New Drug (IND) Application for DCR-AUD for Alcohol Use Disorder – – Announced Interim Phase 1 Results and Initiated Patient Dosing in ESTRELLA Phase 2 Study of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (AATLD) – – Received $10.0 Million Milestone Payment Following FDA Acceptance of Lilly's Second GalXC RNAi IND Application Under Companies' Global Research Collaboration and Licensing Agreement – – Company

      8/9/21 7:00:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria

      – Nedosiran Achieved Primary Endpoint, Demonstrating Statistically and Clinically Significant Sustained Reduction in Urinary Oxalate Excretion; Key Secondary Endpoint Also Achieved; Robust Efficacy Seen in PH1 Participants – – Nedosiran Was Generally Well Tolerated in PHYOX2 With a Safety Profile Similar to Previously Reported PHYOX Trial Results – – Results Further Validate GalXC™ RNAi Technology Platform and its Ability to Silence Disease-Driving Genes – – Management to Host Conference Call and Webcast Today at 4:30 p.m. ET – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutic

      8/5/21 4:01:00 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021

      Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2021 financial results before market open on Monday, Aug. 9, 2021. Management will host a conference call at 8:00 a.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website. The conference call can be accessed by dialing (855) 4

      8/2/21 4:05:00 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million

      Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. OXLUMO, which has been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of primary hyperoxaluria (PH) type 1, is marketed by Alnylam Pharma

      4/8/21 7:40:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million

      LEXINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) and Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. OXLUMO, which has been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of primary hyperoxaluria (PH) type 1, is marketed by Alnylam Pharmaceuticals, Inc. (“Alnylam”). “We are very pleased to have entered into this agreement with Royalty Pharma, which is r

      4/8/21 7:30:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    Dicerna Pharmaceuticals, Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Dicerna Pharmaceuticals, Inc.

      SC 13G - Dicerna Pharmaceuticals Inc (0001399529) (Subject)

      12/3/21 6:09:54 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Dicerna Pharmaceuticals Inc (0001399529) (Subject)

      2/12/21 3:36:29 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Dicerna Pharmaceuticals Inc (0001399529) (Subject)

      2/12/21 10:01:42 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Dicerna Pharmaceuticals Inc (0001399529) (Subject)

      2/4/21 11:40:31 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care